AWM Investment Company Inc. lessened its position in argenx SE – (NASDAQ:ARGX) by 5.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 95,000 shares of the company’s stock after selling 5,000 shares during the quarter. AWM Investment Company Inc. owned 0.30% of argenx worth $7,205,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. DekaBank Deutsche Girozentrale bought a new stake in argenx in the 3rd quarter worth approximately $3,746,000. BB Biotech AG grew its position in argenx by 63.6% in the 3rd quarter. BB Biotech AG now owns 734,739 shares of the company’s stock worth $55,723,000 after purchasing an additional 285,690 shares during the period. FMR LLC grew its position in argenx by 12.3% in the 3rd quarter. FMR LLC now owns 3,475,049 shares of the company’s stock worth $263,548,000 after purchasing an additional 380,661 shares during the period. Artal Group S.A. grew its position in argenx by 23.3% in the 3rd quarter. Artal Group S.A. now owns 185,000 shares of the company’s stock worth $14,030,000 after purchasing an additional 35,000 shares during the period. Finally, Janus Henderson Group PLC grew its position in argenx by 12.0% in the 3rd quarter. Janus Henderson Group PLC now owns 493,649 shares of the company’s stock worth $37,438,000 after purchasing an additional 53,070 shares during the period. 59.52% of the stock is currently owned by institutional investors and hedge funds.
A number of research firms have commented on ARGX. Wedbush reaffirmed an “outperform” rating and issued a $125.00 target price (down previously from $130.00) on shares of argenx in a research report on Monday, November 5th. Piper Jaffray Companies reiterated an “overweight” rating and set a $154.00 price target on shares of argenx in a research note on Monday, September 17th. SunTrust Banks lifted their price target on shares of argenx to $132.00 and gave the stock an “in-line” rating in a research note on Tuesday, September 18th. JMP Securities lifted their price target on shares of argenx to $150.00 and gave the stock an “outperform” rating in a research note on Monday, September 17th. Finally, Zacks Investment Research cut shares of argenx from a “buy” rating to a “hold” rating in a research note on Wednesday, November 14th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $134.38.
WARNING: This story was originally reported by WKRB News and is owned by of WKRB News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.wkrb13.com/2018/11/23/argenx-se-argx-shares-sold-by-awm-investment-company-inc.html.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Featured Story: Stock Selection – What is cash flow?
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.